Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

67.17
+0.53000.80%
Volume:55.55K
Turnover:3.72M
Market Cap:2.29B
PE:-10.38
High:67.26
Open:67.00
Low:66.68
Close:66.64
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:0.34
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:2.54
PE(LYR):-6.91

Loading ...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 04

Nektar Therapeutics to present at Jefferies Global Healthcare Conference via webcast

Reuters
·
May 28

Nektar Therapeutics interim CFO Linda M. Rubinstein files initial beneficial ownership statement

Reuters
·
May 27

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR)

TIPRANKS
·
May 14

Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery

Simply Wall St.
·
May 13

Nektar price target lowered to $80 from $95 at Wedbush

TIPRANKS
·
May 12

Stock Track | Nektar Therapeutics Plummets 5.13% Intraday After Wedbush Cuts Price Target

Stock Track
·
May 11

Nektar Therapeutics Is Maintained at Neutral by Wedbush

Dow Jones
·
May 11

Nektar Therapeutics : Wedbush Cuts Target Price to $80 From $95

THOMSON REUTERS
·
May 11

Nektar Therapeutics Charts Aggressive Path With REZPEG

TIPRANKS
·
May 09

Nektar Therapeutics Establishes New Equity Distribution Agreement

TIPRANKS
·
May 09

Nektar Therapeutics Names Rubinstein New Interim CFO

Dow Jones
·
May 09

BRIEF-Nektar Therapeutics May Offer And Sell Common Stock Up To $150 Million - SEC Filing

Reuters
·
May 09

Nektar Therapeutics - to Offer up to $150 Mln in Common Stock via Equity Distribution Agreement - SEC Filing

THOMSON REUTERS
·
May 09

Nektar Therapeutics - Sandra Gardiner to Retire as Interim CFO Effective May 15, 2026 - SEC Filing

THOMSON REUTERS
·
May 09

Nektar enters equity distribution deal for up to $150 million at-the-market offering

Reuters
·
May 09

Nektar Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 08

Nektar price target raised to $192 from $105 at Piper Sandler

TIPRANKS
·
May 08

Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating

TIPRANKS
·
May 08

Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)

TIPRANKS
·
May 08